Summary of I-DXd in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) with and without Brain Metastases
This text details the efficacy and safety of a treatment called I-DXd in patients with ES-SCLC, specifically looking at how it performs in those with and without brain metastases at the start of treatment.
Key Findings:
* Efficacy is good in both groups: I-DXd showed a good overall response rate (cORR) in both patients with (46.2%) and without (50.0%) baseline brain metastases. Disease control rate (cDCR) was also high in both groups (89.2% and 86.1% respectively).
* Similar Overall Survival (OS) & Progression-Free Survival (PFS): OS and PFS where comparable between patients with and without pre-existing brain metastases (OS ~10 months in both groups, PFS ~4.5-5.4 months).
* Intracranial efficacy: I-DXd demonstrated effectiveness within the brain, nonetheless of prior brain radiation therapy. The CNS cORR (response in the brain) was good, notably in those who hadn't received prior brain radiation (71.4%).
* Potential to Prevent Brain metastases: The rate of brain progression was relatively low, suggesting I-DXd might help prevent new brain metastases. The rate of brain progression was lower in those without prior brain radiation.
* Safety: I-DXd is associated with a high rate of treatment-related adverse events (TRAEs) - 87.7% in those with brain metastases and 91.7% in those without. However, these were manageable, with dose adjustments made as needed. More severe (Grade 3+) TRAEs were more common in those without baseline brain metastases (41.7% vs 30.8%).